This 2016 review explores the integration of pharmacogenetic and nutrigenetic strategies into obesity management, emphasizing personalized treatment plans based on genetic profiles. It discusses the efficacy of FDA-approved anti-obesity drugs—such as orlistat, lorcaserin, liraglutide, phentermine/topiramate, and bupropion/naltrexone—and highlights how genetic variations can influence individual responses to these medications. The review
